Stockreport

Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight

Verona Pharma plc - American Depositary Shares  (VRNA) 
US:NASDAQ Investor Relations: nasdaq.com/symbol/vrna/real-time
PDF After over a decade without notable progress in treating chronic obstructive pulmonary disease, patients with this ongoing condition now have two new treatment options, [Read more]